Neuraxpharm expands in Southeast Europe
pharmafile | March 8, 2022 | News story | Manufacturing and Production |
Neuraxpharm Group have announced the expansion of its business in Southeast Europe, through the acquisition of Brain Therapeutics, a company with longstanding expertise in commercialisation of central nervous system (CNS) products in Greece, Cyprus, and the Balkan countries.
Neuraxpharm is a leading European specialty pharmaceutical company focused on the CNS, and with the latest acquisition, reinforces its aim to offer a wide variety of first-class CNS products in a growing number of countries.
Brain Therapeutics is a CNS-focussed marketing and distribution company headquartered in Athens. The company specialises in the in-licensing and commercialisation of pharmaceutical products in the CNS therapy area, to address the unmet medical needs of patients with mental, neurological, neurodevelopment or neurodegenerative disorders, as well as anaesthesia and pain.
Commenting on the transaction, Dr Jörg-Thomas Dierks, CEO of Neuraxpharm, commented: “The acquisition of Brain Therapeutics will significantly strengthen our successful activities in the commercialization of CNS products in Greece, Cyprus and the Balkan countries. We are excited to be able to supply patients in Southeast Europe with our products more efficiently in future. This acquisition brings us one step closer to our goal of addressing the unmet medical needs of CNS patients across Europe.”
Having acquired Brain Therapeutics, Neuraxpharm is now able to bring new products to the Greek market since the platform offers a unique level of local market access. The commercial expertise of Brain Therapeutics and the availability of necessary licenses for the broad product portfolio will enable Neuraxpharm to expand its offering rapidly and build on its position as a CNS specialist in Southeast Europe. The market-leading product Buccolam®, emergency treatment of children and adolescents with epilepsy, will be among the products to be offered.
George Pavlakis, Founder of Brain Therapeutics, added: “We are delighted to become part of a leading European CNS player and look forward to working with the dynamic, experienced and high performing team at Neuraxpharm. We are excited about our future with the Neuraxpharm Group and the opportunity to contribute our expertise in the CNS field. Together, we will be able to provide further innovative CNS products to patients in Greece and Southeast Europe.”
